Go Prime
New Research on Neoantigens and Tumor-targeting T-cells Marks Paradigm Shift in Countering Solid Tumors
2021-11-19
Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion
2021-11-18
With New Funding, ACELYRIN Licenses First Therapeutic and Leaps into Late-Stage Trials for Autoimmune Diseases
2021-11-17
Scientists Engineer RNA Switches for Targeted Delivery of Gene Therapy and RNA Therapeutics
2021-11-07
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115